Anti-DcR1 抗体 (ab2087)
Key features and details
- Rabbit polyclonal to DcR1
- Suitable for: ICC/IF, WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
製品の概要
-
製品名
Anti-DcR1 antibody
DcR1 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to DcR1 -
由来種
Rabbit -
アプリケーション
適用あり: ICC/IF, WBmore details -
種交差性
交差種: Mouse, Rat, Human -
免疫原
Synthetic peptide:
CKEGTFRNENSPE
, corresponding to amino acids 111-123 of Human DcR1. -
ポジティブ･コントロール
- HeLa whole cell lysate.
-
特記事項
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumour cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy-receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.2
Preservative: 0.02% Sodium azide -
Concentration information loading... -
精製度
Affinity purified -
一次抗体 備考
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumour cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy-receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
アプリケーション
Our Abpromise guarantee covers the use of ab2087 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| ICC/IF | Use a concentration of 10 µg/ml. | |
| WB | Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 65 kDa. Can be blocked with DcR1 peptide (human). |
ターゲット情報
-
関連性
DcR1 / TRAIL-R3 / TRID / LIT is one of the two putative decoy receptors identified for TRAIL, one of the members of TNF family of apoptosis inducing proteins. The other putative decoy receptor is called DcR2 / TRUNDD / TRAIL-R4. DcR1 is attached to the cell surface through glycophospholipid anchor. It has the extracellular TRAIL binding domain but lacks the cytoplasmic domain to induce apoptotic signal. Hence overexpression of DcR1 inhibits the TRAIL induced apoptosis. -
細胞内局在
Cell Membrane and Cytoplasmic -
参照データベース
- Entrez Gene: 8794 Human
- Omim: 603613 Human
- SwissProt: O14798 Human
-
別名
- Antagonist decoy receptor for TRAIL/Apo 2L antibody
- CD263 antibody
- Cytotoxic TRAIL receptor 3 antibody
see all
画像
-
Western blot - Anti-DcR1 antibody (ab2087)All lanes : Anti-DcR1 antibody (ab2087) at 1 µg/ml
Lane 1 : Hela cell lysate
Lane 2 : Mouse liver tissue lysate
Lane 3 : Rat liver tissue lysate
Predicted band size: 65 kDaWestern blot analysis of DcR1 in HeLa cell (A), mouse (B) and rat (C) liver tissue lysates with anti-DcR1 (ED2) at 1
µ g/ml. -
Immunocytochemistry/ Immunofluorescence - Anti-DcR1 antibody (ab2087)ab2087 at 10µg/ml staining DcR1 in rat liver tissue by ICC/IF
-
Immunocytochemistry/ Immunofluorescence - Anti-DcR1 antibody (ab2087)Immunofluorescence of DcR1 in Rat Liver cells using ab2087 at 20 ug/ml.
プロトコール
データシートおよび資料
参考文献 (5)
ab2087 は 5 報の論文で使用されています。
- Wang Z et al. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduct Target Ther 5:40 (2020). PubMed: 32327638
- Rath C et al. Comparison of different label-free imaging high-throughput biosensing systems for aptamer binding measurements using thrombin aptamers. Anal Biochem 583:113323 (2019). PubMed: 31129134
- Li N et al. The role of Zeb1 in the pathogenesis of morbidly adherent placenta. Mol Med Rep 20:2812-2822 (2019). PubMed: 31322233
- You C et al. ß-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors. Int J Oncol 53:2258-2268 (2018). PubMed: 30132512
- Ziauddin MF et al. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther 17:550-9 (2010). PubMed: 20182517
